Replies to post #216256 on Elite Pharmaceuticals Inc (ELTP)

[lasers]

The pivotal trial met its primary endpoint (p = 0.001), demonstrating statistical significance that the product provided pain relief following surgery in the treatment group using ELI-200 compared to the placebo group. Secondary endpoint results were consistent with primary findings and included safety measures. There were no serious adverse events or deaths related to ELI-200 reported during the conduct of the trial.

http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&GoTopage=1&Category=2163&BzID=2258&t=1955&G=939

[Don'tDrinkTheKoolAid]

Just like the CRL will never see it!